Citation: | Xinju Wang, Jianru Chen, Wei Wu, Jinrong Fan, Luling Huang, Weiwei Sun, Kaiqiao He, Shuli Li, Chunying Li. Circulating Memory T Cells and TCF1+ T Cells Aid in Diagnosis and Monitor Disease Activity in Vitiligo[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2024.100998 |
[1] |
K. Ezzedine, V. Eleftheriadou, M. Whitton, et al., Vitiligo, Lancet 386 (2015) 74-84.
|
[2] |
M.W. Linthorst Homan, P.I. Spuls, J. de Korte, et al., The burden of vitiligo: Patient characteristics associated with quality of life, J. Am. Acad. Dermatol. 61 (2009) 411-420.
|
[3] |
K. Boniface, J. Seneschal, M. Picardo, et al., Vitiligo: Focus on clinical aspects, immunopathogenesis, and therapy, Clin. Rev. Allergy. Immunol. 54 (2018) 52-67.
|
[4] |
M. Cavalie, K. Ezzedine, E. Fontas, et al., Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: A randomized, double blind, placebo-controlled study, J. Invest. Dermatol. 135 (2015) 970-974.
|
[5] |
J.M. Richmond, J.P. Strassner, M. Rashighi, et al., Resident memory and recirculating memory T cells cooperate to maintain disease in a mouse model of vitiligo, J. Invest. Dermatol. 139 (2019) 769-778.
|
[6] |
R.L. Riding, J.E. Harris, The Role of Memory CD8+ T Cells in Vitiligo, J. Immunol. 203 (2019) 11-19.
|
[7] |
K. Boniface, C. Jacquemin, A.S. Darrigade, et al., Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3, J. Invest. Dermatol. 138 (2018) 355-364.
|
[8] |
C. Martins, A.S. Darrigade, C. Jacquemin, et al., Phenotype and function of circulating memory T cells in human vitiligo, Br. J. Dermatol. 183 (2020) 899-908.
|
[9] |
X. Zhao, Q. Shan, H.H. Xue, TCF1 in T cell immunity: A broadened frontier, Nat. Rev. Immunol. 22 (2022) 147-157.
|
[10] |
I. Siddiqui, K. Schaeuble, V. Chennupati, et al., Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy, Immunity. 50 (2019) 195-211.e10.
|
[11] |
B.C. Miller, D.R. Sen, R. Al Abosy, et al., Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade, Nat. Immunol. 20 (2019) 326-336.
|
[12] |
R.L. Rutishauser, C.D.T. Deguit, J. Hiatt, et al., TCF-1 regulates HIV-specific CD8+ T cell expansion capacity, JCI Insight 6 (2021), e136648.
|
[13] |
R. Maniar, P.H. Wang, R.S. Washburn, et al., Self-renewing CD8+ T-cell abundance in blood associates with response to immunotherapy, Cancer Immunol. Res. 11 (2023) 164-170.
|
[14] |
L.M. Snell, B.L. MacLeod, J.C. Law, et al., CD8+ T cell priming in established chronic viral infection preferentially directs differentiation of memory-like cells for sustained immunity, Immunity 49 (2018) 678-694.e5.
|
[15] |
S.V. Gearty, F. Dundar, P. Zumbo, et al., An autoimmune stem-like CD8 T cell population drives type 1 diabetes, Nature 602 (2022) 156-161.
|
[16] |
T. Lei, A. Xu, T. Gao, et al., Consensus on the diagnosis and treatment of vitiligo in china (2021 Revision), Int. J. Dermatol. Venereol. 4 (2021) 10-15.
|
[17] |
G.R. Kanthraj, C.R. Srinivas, S.D. Shenoi, et al., Comparison of computer-aided design and rule of nines methods in the evaluation of the extent of body involvement in cutaneous lesions, Arch. Dermatol. 133 (1997) 922-923.
|
[18] |
F. Sallusto, D. Lenig, R. Forster, et al., Two subsets of memory T lymphocytes with distinct homing potentials and effector functions, Nature 401 (1999) 708-712.
|
[19] |
J.M. Richmond, J.P. Strassner, K.I. Essien, et al., T-cell positioning by chemokines in autoimmune skin diseases, Immunol. Rev. 289 (2019) 186-204.
|
[20] |
F. Shah, S. Patel, R. Begum, et al., Emerging role of tissue resident memory T cells in vitiligo: From pathogenesis to therapeutics, Autoimmun. Rev. 20 (2021), 102868.
|
[21] |
F. Shah, P.S. Giri, A.H. Bharti, et al., Compromised melanocyte survival due to decreased suppression of CD4+ & CD8+ resident memory T cells by impaired TRM-regulatory T cells in generalized vitiligo patients, Exp. Dermatol. 33 (2024), e14982.
|
[22] |
T. Czarnowicki, H. He, A. Leonard, et al., Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases, J. Allergy Clin. Immunol. 143 (2019) 2095-2107.
|
[23] |
C.M. Mousset, W. Hobo, R. Woestenenk, et al., Comprehensive phenotyping of T cells using flow cytometry, Cytometry A. 95 (2019) 647-654.
|
[24] |
E.J. Wherry, V. Teichgraber, T.C. Becker, et al., Lineage relationship and protective immunity of memory CD8 T cell subsets, Nat. Immunol. 4 (2003) 225-234.
|
[25] |
J.J. Goronzy, C.M. Weyand, T cell development and receptor diversity during aging, Curr. Opin. Immunol. 17 (2005) 468-475.
|
[26] |
V. Eleftheriadou, R. Atkar, J. Batchelor, et al., British Association of Dermatologists guidelines for the management of people with vitiligo 2021, Br. J. Dermatol. 186 (2022) 18-29.
|
[27] |
N. van Geel, L. Depaepe, V. Vandaele, et al., Assessing the dynamic changes in vitiligo: reliability and validity of the Vitiligo Disease Activity Score (VDAS) and Vitiligo Disease Improvement Score (VDIS), J. Eur. Acad. Dermatol. Venereol. 36 (2022) 1334-1341.
|
[28] |
N. van Geel, T. Passeron, A. Wolkerstorfer, et al., Reliability and validity of the Vitiligo Signs of Activity Score (VSAS), Br. J. Dermatol. 183 (2020) 883-890.
|
[29] |
K. He, W. Wu, X. Wang, et al., Circulatory levels of alarmins in patients with non-segmental vitiligo: Potential biomarkers for disease diagnosis and activity/severity assessment, Front. Immunol. 13 (2022) 1069196.
|
[30] |
S. Li, W. Dai, S. Wang, et al., Clinical significance of serum oxidative stress markers to assess disease activity and severity in patients with non-segmental vitiligo, Front. Cell. Dev. Biol. 9 (2021), 739413.
|
[31] |
R. Speeckaert, J. Lambert, N. van Geel, Clinical significance of serum soluble CD molecules to assess disease activity in vitiligo, JAMA Dermatol. 152 (2016) 1194-1200.
|
[32] |
J.P. Strassner, M. Rashighi, M. Ahmed Refat, et al., Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity, J. Am. Acad. Dermatol. 76 (2017) 847-855.e5.
|
[33] |
X.X. Wang, Q.Q. Wang, J.Q. Wu, et al., Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo, Br. J. Dermatol. 174 (2016) 1318-1326.
|
[34] |
I. Odak, J. Barros-Martins, B. Bosnjak, et al., Reappearance of effector T cells is associated with recovery from COVID-19, EBioMedicine 57 (2020), 102885.
|
[35] |
R. Kratchmarov, A.M. Magun, S.L. Reiner, TCF1 expression marks self-renewing human CD8+ T cells, Blood Adv. 2 (2018) 1685-1690.
|
[36] |
M.C. van Aalderen, M. van den Biggelaar, E.B.M. Remmerswaal, et al., Label-free analysis of CD8+ T cell subset proteomes supports a progressive differentiation model of human-virus-specific T cells, Cell Rep. 19 (2017) 1068-1079.
|
[37] |
P. Durek, K. Nordstrom, G. Gasparoni, et al., Epigenomic profiling of human CD4+ T cells supports a linear differentiation model and highlights molecular regulators of memory development, Immunity 45 (2016) 1148-1161.
|
[38] |
J.G. van den Boorn, D. Konijnenberg, T.A. Dellemijn, et al., Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients, J. Invest. Dermatol. 129 (2009) 2220-2232.
|
[39] |
B. Palermo, R. Campanelli, S. Garbelli, et al., Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: The role of cellular immunity in the etiopathogenesis of vitiligo, J. Invest. Dermatol. 117 (2001) 326-332.
|